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The tumor necrosis factor receptor 1 (TNFR1) and the
Fas receptor recruit complexes formed by the
interactions between RIP kinase, TRADD, FADD and
RAIDD — adaptor proteins that contain death
domains – which in turn recruit other proteins to initiate
signaling [1–5]. To identify proteins associated with the
TNF signaling pathway, we performed a yeast two-
hybrid interaction screen using RIP as bait. We isolated
a kinase, RIP3, which shares homology with the kinase
domain of RIP and RIP2 (also known as Rick or
CARDIAK). RIP3 could be co-immunoprecipitated with
RIP, TRAF2 and TNFR1 in mammalian cells. The
carboxy-terminal domain of RIP3, like that of RIP, could
activate the transcription factor NFκB and induce
apoptosis when expressed in mammalian cells.
Interestingly, this region shares no significant sequence
homology to the death domain of RIP, the caspase-
recruiting domain (CARD) of RIP2 [6–8] or any other
apoptosis-inducing domain. As with RIP and RIP2, the
kinase domain of RIP3 was not required for either NFκB
activation or apoptosis induction. Overexpression of a
dominant-negative mutant of RIP3 strongly inhibited
the caspase activation but not the NFκB activation
induced by TNFα. Therefore, RIP3 appears to function
as an intermediary in TNFα-induced apoptosis. 
Addresses: *Rigel, Inc., 240 East Grand Ave, South San Francisco,
California 94080, USA. †Department of Molecular Pharmacology,
Department of Microbiology and Immunology, Stanford University
Medical Center, Stanford University, Stanford, California 94305, USA.
Correspondence: Ying Luo
E-mail: yluo@rigel.com 
Received: 11 November 1998
Revised: 26 March 1999
Accepted: 16 April 1999
Published: 10 May 1999
Current Biology 1999, 9:539–542
http://biomednet.com/elecref/0960982200900539
© Elsevier Science Ltd ISSN 0960-9822
Results and discussion
Several known TNFα signaling proteins have been shown
to bind RIP [2]. We established a large-scale yeast two-
hybrid screening system designed to isolate rare mRNAs
and identify novel protein–protein interactions. Using RIP
as bait, we screened 96 million independent yeast trans-
formants in a single round of transformation with a cDNA
library combined from Hela cells and lymphocytes. As
expected, many known RIP-binding proteins, including
TRAF1, TRAF2, TNFR1, RIP, TRADD and FADD,
were cloned; several novel genes were isolated as well.
One of the newly identified cDNAs had high sequence
homology with RIP, and the full-length cDNA contained
a 518 amino acid open-reading frame. Analysis of the
amino acid sequence of this protein revealed a kinase
domain (between amino acid residues 21 and 287) that
had 47% homology to the kinase domain of RIP and 42%
homology to that of RIP2; consequently, the protein was
designated RIP3 (see Supplementary material published
with this paper on the internet). Outside the kinase
domain, however, the carboxy-terminal region of RIP3
had no homology to death domains [3], death effector
domains [9] or the CARD region [10]. An approximately
2.1 kb transcript was detected with a cDNA probe specific
to RIP3 in both normal human tissue and human tumor
RNA blots (see Supplementary material). 
To analyze which region of RIP3 was important for interac-
tions with RIP, a series of deletion mutants and a point
mutant were engineered (Figure 1a). In yeast, the interme-
diate region (amino acids 82–436) of RIP3 was required for
the interaction between RIP and RIP3 (Figure 1c). Co-
immunoprecipitation analysis was performed to verify the
interaction of RIP with RIP3 by co-transfection of hemag-
glutinin (HA)-tagged RIP with FLAG-tagged full-length
and truncated mutants of RIP3 in Phoenix-A (293 T) cells.
Figure 1d shows that full-length RIP3, as well as the dele-
tion mutant RIP3(82–518) and the point mutant
RIP3(K50D), co-immunoprecipitated with RIP. Interest-
ingly, the RIP3(1–436) deletion mutant had dramatically
reduced binding affinity for RIP. No association was
detected between RIP and RIP3(1–251), RIP3(1–196) or
RIP3(287–518). This suggests that the interaction between
RIP3 and RIP is mediated by a portion of the kinase
domain of RIP3 with additional contribution from the
carboxy-terminal domain. To test whether RIP3 was able
to bind to endogenous RIP, FLAG–RIP3 was transfected
into Phoenix-A cells in the presence and absence of TNFα.
Ectopically expressed RIP3 was able to bind to endoge-
nous RIP (Figure 1e) and TNFα treatment did not signifi-
cantly affect this binding. In addition, endogenous TNFR1
was co-immunoprecipitated with ectopically expressed
RIP3, and endogenous RIP3 was co-immunoprecipitated
with ectopically expressed TRAF2 (Figure 1f). Interaction
between TRAF2 and RIP3 was also verified by the yeast
two-hybrid system (data not shown). This suggests that
RIP3 is part of the TNFR1 signaling complex.
RIP3 contains consensus Ser/Thr kinase phosphorylation
motifs. An in vitro kinase assay demonstrated that RIP3 was
a kinase and was autophosphorylated. The Lys50 residue of
the RIP3 kinase domain, homologous to the conserved
lysine in RIP that is critical for enzymatic activity and ATP
binding [6,7], was substituted with aspartic acid. This
RIP3(K50D) mutant lacked kinase activity (Figure 1b), sug-
gesting that this lysine is required for autophosphorylation.
To test whether RIP3 was able to induce cell death,
Phoenix-A cells were co-transfected with a eukaryotic
RIP3 expression plasmid together with a pGDB control
plasmid expressing green fluorescent protein (GFP) to
assess transfection efficiency [11]. The GFP-positive
RIP3-transfected cells displayed morphological character-
istics of apoptosis, including detachment from the plate
substrate and resultant ‘rounding up’ and a condensed
and fragmented nucleus [12] (data not shown and see
Supplementary material). RIP3-induced apoptosis was
also observed in Hela cells (data not shown). Figure 2a
shows that approximately 35% of the cells transfected
with RIP3 underwent apoptosis, compared with only 2%
of the cells transfected with control vector. The carboxy-
terminal deletion mutant, RIP3(1–436), failed to induce
apoptosis. Similarly to RIP [2] and RIP2 [6], deletion of
the RIP3 kinase domain had no effect on its apoptotic
activity  (data not shown), suggesting that the kinase
domain was not required for RIP3-mediated cell death. 
Apoptosis induced by TNFα and Fas ligand is controlled
by caspase activation [13]. RIP2 has also been reported to
induce apoptosis by enhancing caspase activity [7]. To test
whether RIP3 activates cellular caspases, a RIP3 expression
vector, pYCI-RIP3, was co-transfected into Phoenix-A cells
with pGDB. The pGDB plasmid expresses a previously
described hybrid protein of GFP and blue fluorescent
protein (BFP) linked by a peptide containing the sequence
DEVD and is used as a reporter of intracellular caspase
activity [11] (Figure 2b). When caspases 2, 3 or 7 are acti-
vated, they specifically cleave appropriately accessible 
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Figure 1
The association of RIP3 with RIP. All
transfections were carried out using the
calcium phosphate method. (a) The RIP3
truncation mutants and the RIP3(K50D)
mutant in which Lys50 is mutated to aspartic
acid. The kinase domain of RIP3 is shaded.
(b) RIP3, but not RIP3(K50D), is
autophosphorylated. Phoenix-A cells were
transfected with a FLAG vector, or plasmids
expressing FLAG–RIP3 or
FLAG–RIP3(K50D) (1 µg) and an in vitro
kinase assay performed after
immunoprecipitation through the FLAG
epitope (top panel). The lysates were
immunoblotted (WB) with an anti-FLAG
monoclonal antibody and the protein amounts
adjusted accordingly before performing the
immunoprecipitations (the protein levels
before adjustment are shown in the bottom
panel). (c) Summary of the binding of RIP to
RIP3 and the RIP3 mutants in the yeast two-
hybrid system. (d) RIP3 associates with RIP in
mammalian cells. Cell lysates were prepared
from Phoenix-A cells 24 h after co-transfection
of plasmids (5 µg) expressing HA–RIP and
either FLAG protein (control) or one of the
indicated FLAG–RIP3 proteins.
Co-precipitated FLAG–RIP3 proteins were
detected by immunoblotting (WB) with an
anti-FLAG polyclonal antibody after
immunoprecipitation (IP) with anti-HA
antibodies (top panel). The protein levels
before adjustment for the
immunoprecipitations are shown in the middle
and bottom panels, detected by anti-FLAG
and anti-HA antibodies, respectively. (e) TNFα
does not enhance the association of RIP3 to
endogenous RIP. Phoenix-A cells were
transfected with a FLAG vector or a
FLAG–RIP3 expression plasmid (10 µg;
RIP3). After 18 h, cells were treated with
20 ng/ml human TNFα for 10 or 30 min or left
untreated. The cells were then harvested
immediately and proteins immunoprecipitated
(IP) with an anti-FLAG antibody and
immunoblotted (WB) with a goat anti-RIP
polyclonal antibody. (f) RIP3
co-immunoprecipitates with TRAF2 and
TNFR1. A control vector or a FLAG-tagged
TRAF2 expression plasmid were transfected
into cells. Following immunoprecipitation (IP)
with an anti-FLAG antibody, association with
endogenous RIP3 was detected with an anti-
RIP3 antibody (WB; left panel). In the right
panel, control vector or a FLAG–RIP3
expression plasmid were transfected into
cells. Following immunoprecipitation with an
anti-RIP3 antibody, association with
endogenous TNFR1 was detected with an
anti-TNFR1 antibody.
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substrates at the DEVD sequence [12], so GFP and BFP
monomers would be released. Western blot analysis using
an anti-GFP monoclonal antibody indicated that ectopic
expression of RIP3 activated caspases that cleaved the
DEVD linker peptide, releasing GFP and BFP monomers
(Figure 2b). A broad-spectrum inhibitor of caspases, termed
zVAD-fmk [14], inhibited the caspase activity triggered by
RIP3 expression (data not shown). This result confirmed
that cleavage of the chimeric protein was due to caspase
activation. RIP3-induced apoptosis could also be inhibited
by the caspase inhibitor CrmA (data not shown). Amino-ter-
minal deletion mutants RIP3(82–518) and RIP3(287–518),
and RIP3(K50D), were still able to activate caspase activity
(Figure 2b). Deletion of the carboxy-terminal region of
RIP3 — constructs RIP3(1–251) and RIP3(1–436) — com-
pletely abrogated caspase activation (Figure 2b). These
results again indicate that the kinase activity of RIP3 is not
required for activation of caspases and cell death. As the
carboxy-terminal domain (amino acids 437–518) of RIP3 is
not required for the binding of RIP3 to RIP, this region
might bind other proteins involved in unknown pathway(s)
that stimulate apoptosis. It is not known whether the
carboxy-terminal region of RIP3 is able to bind directly to
any known death adaptor or death protease. Additional two-
hybrid screening using RIP3 as bait is being carried out to
find signaling proteins downstream of RIP3. 
We also tested whether RIP3 could induce NFκB activa-
tion. Phoenix-A cells were harvested for a luciferase
reporter assay 24 hours after co-transfection with an NFκB-
dependent luciferase reporter construct and pYCI-RIP3.
Ectopic expression of RIP3 alone induced NFκB activa-
tion approximately sevenfold (Figure 2c). The NFκB acti-
vation could be inhibited by co-transfection of an IκB
dominant-negative mutant (data not shown). The carboxy-
terminal region of RIP3 was essential for NFκB activation,
as RIP3(1–251) and RIP3(1–436) were not able to activate
NFκB. Interestingly, RIP3(K50D), RIP3(82–518) and
RIP3(287–518) induced higher luciferase activity than full-
length RIP3 (Figure 2c). This suggests that the kinase
domain of RIP3 is not required for the NFκB activation. In
contrast, RIP3 had no noticeable effect on activation path-
ways mediated by the transcription factor AP-1 (data
not shown). 
Although RIP3 associates with RIP and TRAF2 and acti-
vates apoptosis and NFκB, its function in the TNFα sig-
naling pathway needs to be dissected. In overexpression
experiments, RIP3(1–436) inhibited TNFα-induced
caspase activation (Figure 3b) but not TNFα-induced
NFκB activation (data not shown), suggesting that RIP3
is involved in the TNFα-mediated apoptosis pathway.
These results imply that without the carboxy-terminal
domain (amino acids 437–518), RIP3 either competes
with or fails to recruit other proteins of the TNF signal-
ing complex required for the activation of caspases. In
separate experiments, RIP3(1–436) was able to downreg-
ulate RIP-mediated apoptosis activation: whereas
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(c)
Expression of RIP3 activates apoptosis and NFκB in Phoenix-A cells.
(a) The carboxy-terminal deletion mutant failed to induce cell death.
Empty vector, or plasmids expressing wild-type RIP3 or RIP3(1–436)
(3 µg) were co-transfected with pGDB (1 µg) into Phoenix-A cells.
Hoechst-stained apoptotic cells were examined and counted by
fluorescence microscopy. The data are expressed as the percentage of
apoptotic cells among the total number of cells counted. (b) The
carboxy-terminal region of RIP3 induces caspase activity. Phoenix-A
cells (2 × 106) were co-transfected with empty vector or with plasmids
expressing wild-type RIP3 or the indicated RIP3 mutants (10 µg),
together with pGDB (3 µg). Lysates were analyzed by a western blot
(WB) probed with anti-GFP monoclonal antibody. Caspase cleavage
released the monomeric GFP as indicated (monomer). The structure of
the reporter pGDB encoding the GFP–BFP chimeric protein is shown
below. The arrow indicates the caspase cleavage site. (c) The carboxy-
terminal region of RIP3 is required for NFκB activation. NFκB reporter
activity was determined by a luciferase assay after transiently
co-transfecting Phoenix-A cells with empty vector or the indicated
RIP3 expression plasmids (3 µg), an NFκB-dependent luciferase
reporter plasmid (1 µg), and a Renilla luciferase expression plasmid
(0.13 µg). The calcium phosphate precipitation method was used for
transfection. The level of expressed tagged proteins was monitored by
western blot analysis (data not shown). 
co-transfection of full-length RIP3 (3 µg) with RIP
(0.1 µg) resulted in greater caspase activity than with RIP
alone (Figure 3a), RIP3(1–436) significantly reduced
RIP-induced caspase activity (Figure 3a). In contrast,
although RIP3 alone was able to activate NFκB, co-trans-
fection of RIP (0.3 µg) and full-length RIP3 (3 µg) in
Phoenix-A cells did not have any synergistic effect on
NFκB activation. When RIP3(1–436) was co-transfected
with RIP, the RIP-mediated NFκB activation was only
slightly reduced (see Supplementary material). Another
RIP3 mutant (amino acids 287–518) was still able to acti-
vate caspases and NFκB, even though it did not bind
RIP (data not shown). 
In summary, we have demonstrated that RIP3 is a novel
kinase associated with the TNFα signaling complex. RIP3
binds to RIP and TRAF2 in both yeast and mammalian
cells and co-immunoprecipitates with TNFR1. Although
RIP is an essential player in TNFα-induced NFκB activa-
tion [15], and RIP3 was cloned by binding to RIP, the
function of RIP3 might not rely solely on its binding to
RIP. A dominant-negative form of RIP3 can inhibit
TNFα-induced caspase activation without affecting
TNFα-induced NFκB activation, suggesting that RIP3
might be involved in TNFα-induced apoptosis. It is possi-
ble that RIP3 and RIP are therefore involved in two dif-
ferent areas of TNFα signaling: apoptosis and NFκB
activation, respectively. The precise role of RIP3 in
TNFα signaling may be answered in the future by
‘knock-out’ experiments. 
Supplementary material
Figures showing RIP3 expression in human tissues, RIP kinase
sequences, Phoenix-A cells undergoing apoptosis after transfection
with RIP3, and the partial reduction of RIP-mediated NFκB activation
by RIP3(1–436) are published with this paper on the internet.
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Figure 3
A RIP3 mutant reduces RIP-activated and TNFα-activated caspase
activity. (a) RIP3(1–436) significantly decreases RIP-induced caspase
activity. Phoenix-A cells were co-transfected with empty vector, or
plasmids expressing wild-type RIP3 or RIP3(1–436) (3 µg), together
with pGDB (0.3 µg) and an RIP plasmid (0.1 µg). After 24 h, cells
were harvested and lysates analyzed by immunoblotting (WB) with
anti-GFP monoclonal antibodies. (b) RIP3(1–436) significantly
decreases TNFα-induced caspase activity. Phoenix-A cells were
transfected as described above and were treated with 10 ng/ml TNFα
plus 10 µg/ml cycloheximide (CHX).
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S1Supplementary material
Figure S1
(a) The kinase domain of RIP3. The predicted Ser/Thr kinase domain
of RIP3, homologous to the kinase domains of RIP and RIP2, is
shaded in the schematic diagram and underlined in the sequence.
(b) RIP3 mRNA is expressed in most human tissues. Normal human
tissue (upper panels) and human tumor tissue (lower panels) mRNA
blots, normalized against β-actin mRNA, were probed with a 32P-
labeled cDNA specific for RIP3 to reveal a 2.1 kb transcript. The tumor
tissue cell lines used were HL-60, Hela (S3), K562, lymphoblastic
leukemia (MOLT-4), Raji, colorectal adenocarcinoma (SW480), lung
carcinoma (A549) and melanoma (G361). 
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Figure S2
CLUSTAL W alignment of RIP, RIP3 and
RIP2. The black boxes indicate identical
amino acid residues and grey boxes indicate
similar amino acid residues. Dashes indicate
skipped residues in the sequences. 
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516 TMPFSSLP PTDESIKYTIYNSTGIQIGAYNYMEIGGTSSSL LDSTNTNFKEEPAAKYQAI
443 --PVTGRP------LVNIYNCSGVQVGDNNYLTMQQTT---AL---PTWGLAPSGKGR-G
458 ----QSLD--------ALLSRD LIMKEDYELVSTKPTR---TS---KVRQLLDTTDIQ--
541   p sslp         iyn tgiqigdynymti  Ts          f l psak q
576 FDNTTSLT DKHLDPIRENLGKHWKNCARKLGFTQSQIDEIDHDYERDGLKEKVYQMLQKW
488 --------LQHPPPVGS----------QEG--------------PKD---PEAWSRPQGW
498 --------GEEFAKVIV----------QKL---------------KDN--KQMGLQPYPE
601           h  pv            qkl               kD     vy  pq w
636 VMREGIKGATVGKLAQALHQCSRI DLLSSL IYVSQN
513 YNHSGK------------------------------
523 ILVVSRSPSLNLLQNKSM------------------
661 vmr gk          
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Supplementary material S3
Figure S3
Phoenix-A cells were stained with Hoechst dye after co-transfection
with pGDB (1 µg) plus either empty vector (3 µg) or a plasmid
expressing RIP3 (3 µg). Apoptotic cells were examined by
fluorescence microscopy. 
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Figure S4
RIP3(1–436) partially reduced the RIP-mediated NFκB activation. We
transfected Phoenix-A cells (5 × 105) with NFκB-dependent luciferase
reporter plasmid (1 µg), and Renilla luciferase expression vector
(0.13 µg), RIP3 (3 µg), RIP3(1–436) (3 µg), and RIP (0.3 µg). The
data represent relative luciferase activity (%).
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